Page last updated: 2024-10-28

halothane and Parkinson Disease

halothane has been researched along with Parkinson Disease in 2 studies

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bevan, DR1
Monks, PS1
Calne, DB1
Ohye, C1
Saito, U1
Fukamachi, A1
Narabayashi, H1

Other Studies

2 other studies available for halothane and Parkinson Disease

ArticleYear
Cardiovascular reactions to anaesthesia during treatment with levodopa.
    Anaesthesia, 1973, Volume: 28, Issue:1

    Topics: Anesthesia, Dental; Anesthesia, General; Dihydroxyphenylalanine; Female; Halothane; Humans; Hyperten

1973
An analysis of the spontaneous rhythmic and non-rhythmic burst discharges in the human thalamus.
    Journal of the neurological sciences, 1974, Volume: 22, Issue:2

    Topics: Action Potentials; Anesthesia, General; Barbiturates; Cerebral Palsy; Electroencephalography; Electr

1974